Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$22.00
-HK$0.68(-3.17%)
At close: 4:00 PM EDT
HK$22.00
-HK$0.68(-3.17%)
Day’s Range― - ―
52-Week RangeHK$19.64 - HK$35.34
Previous CloseN/A
Volume2.14M
Average Volume (3M)0.00
Market Cap
HK$21.97B
Enterprise ValueHK$24.84B
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 31, 2027EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.30Price Target Upside78.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.09
Revenue Forecast (FY)HK$1.22B
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationThe sharp acceleration in revenue indicates improving commercial traction for the company’s medical robotics business. If sustained, stronger system adoption can expand the installed base and create additional recurring demand for instruments, consumables, and services over the next several quarters.
Positive Gross MarginA positive gross margin shows that the company retains economic value after direct product costs, providing a foundation for future operating leverage as sales scale. Continued revenue growth could allow fixed development and commercialization expenses to be absorbed more efficiently over time.
Lower LeverageMeaningfully lower leverage reduces balance-sheet pressure relative to the prior year and may improve financial flexibility. A less debt-intensive capital structure can make it easier to fund commercialization and product development while reducing exposure to financing constraints.
Bears Say
Persistent UnprofitabilityThe company remains materially unprofitable, so revenue growth has not yet translated into sustainable earnings. A large net loss can limit internally funded investment, require continued external support, and make the durability of the business model dependent on achieving substantial operating leverage.
Negative Cash GenerationRecurring negative operating and free cash flow indicate that the business is not yet self-funding its operations. Continued cash burn can constrain investment in robotics platforms and commercialization, while increasing reliance on financing or other sources of capital to sustain growth.
Weak Returns And Capital PressureDeeply negative returns on equity show that the capital base is not currently generating acceptable profits and remains under pressure from ongoing losses. Declining equity can reduce financial resilience and leave less capacity to absorb setbacks while the company pursues expansion.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$19.64 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$21.97B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 160 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Aug 27, 2026. The company reported HK$0.035 earnings per share for the quarter.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of HK$0.035 in its last earnings report. Following the earnings report the stock price went up 2.596%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.03%
12-Months-Change
Fundamentals
Return on Equity
-52.78%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$39.30
▲(78.64% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―